Very valid realignment of possible share price reactions to POC...

Very valid realignment of possible share price reactions to POC news and upcoming
possible revenues from our diagnostic division with our partners.
Speaking of partners, from a Monash University study using the Merck drug Ivermectin:

https://www.msn.com/en-au/news/coro...9-in-lab/ar-BB1277Ux?ocid=spartandhp[/BCOLOR]

"We found that even a single dose could essentially remove all viral RNA (effectively removed all genetic material of the virus) by 48 hours and that even at 24 hours there was a really significant reduction in it," Monash Biomedicine Discovery Institute's Dr Kylie Wagstaff said on Friday.

While it's not known how Ivermectin works on the virus, the drug likely stops the virus dampening the host cells' ability to clear it.

From 2015, Merck's Ivermectin:
Previous news on the drug:

Advertise with Mother Jones​

Earlier today, the Nobel committee awarded its renowned prize for medicine to the discoverers of two anti-parasitic drugs — one that fights malaria and one that treats two lesser-known devastating diseases.
The latter, ivermectin, treats lymphatic filariasis and river blindness, which are parasites that have plagued humans for centuries and currently threaten 1.35 billion people around the world. Developing drugs to treat infectious diseases and making them available to the often-impoverished people who need them is extremely difficult. But because of a breakthrough and an unprecedented move by one of the largest pharmaceutical companies in the world, these diseases might soon be eradicated.

Ivermectin anti- parasitic drug has real potential in providing some early treatment options for those with severe symptoms of the novel virus.
So much about being with the right partners at the right time, !

All IMO
​